Dr Agarwal’s Health Care, an eye care services provider backed by Temasek Holdings and TPG, has filed preliminary documents with the capital markets regulator to raise an estimated Rs 3,000-3,500 crore through its initial public offering (IPO). This marks a significant move for the company, which is a leader in India’s eye care services market.

The IPO will consist of two main components:

Fresh issue of shares up to Rs 300 crore
Offer For Sale (OFS) of up to 6.95 crore equity shares by promoters and selling shareholders, including Arvon Investments Pte. Ltd, Claymore Investments (Mauritius) Pte. Ltd, and Hyperion Investments Pte. Ltd.

In addition, a portion of the IPO will be reserved for eligible employees, as detailed in the company’s draft red herring prospectus (DRHP). According to the draft papers filed, the fresh issue proceeds Rs 195 crore will primarily be used to reduce debt. The remaining funds will go towards general corporate purposes and potential unidentified acquisitions as part of the company’s expansion plans.

Dr Agarwal’s Health Care has built a strong reputation in India, offering a broad range of eye care services including:
Cataract surgeries
Refractive surgeries
Consultations
Diagnosis
Non-surgical treatments

The company also sells optical products, contact lenses, accessories, and eye care-related pharmaceutical items. According to a CRISIL MI&A report, Dr Agarwal’s Health Care commanded 25% of the total eye care service chain market in India during FY 2024.

As of March 31, 2024, Dr Agarwal’s Health Care operated 180 facilities, of which 165 were in India, with a significant presence in South India, particularly in Chennai, Hyderabad, and Bengaluru, followed by Western India. This extensive network has helped the company maintain its strong position in the eye care market.

On the financial front, Dr Agarwal’s Health Care reported:
Revenue from operations: Rs 1,332.15 crore in Fiscal 2024
Profit after tax: Rs 95.05 crore

The IPO is being led by several prominent investment banks, including Kotak Mahindra Capital Company, Morgan Stanley India Company, Jefferies India, and Motilal Oswal Investment Advisors.
With strong financial performance and ambitious expansion plans, Dr Agarwal’s Health Care’s IPO is expected to attract significant interest from both institutional and retail investors. The funds raised will not only help in reducing the company’s debt but also fuel future growth through potential acquisitions and broader market penetration.

Over the past 12 months, the Indian hospital sector has experienced significant growth on the stock market. However, some analysts caution that the upward trend may be approaching its limit and hospital stocks are now “expensively” priced, exceeding their fundamental valuations.

In the past year, most hospital stocks have outpaced the benchmark equity index, BSE Sensex, which gained 22%.

Notable performers include:

Wockhardt: +250%
Aashka Hospitals: +143%
Dr Agarwals Eye Hospital: +126%
Global Health: +80%
Kovai Medical Center & Hospital: +63.20%
Max Healthcare Institute: +48%
Fortis Healthcare: +45%

Analysts points out a divergence between stock valuations and earnings growth, suggesting a potential correction for overvalued hospital stocks. Despite this, they remain cautiously optimistic about the healthcare sector, highlighting companies like Healthcare Global and Aster DM Healthcare as “reasonably priced” and well-positioned for future earnings growth.

Analysts optimism is extended to the diagnostics sector, anticipating a “re-rating” over the next few years due to increased market valuations driven by positive sentiment and growth opportunities. Notable performers in the diagnostics space include:

Vijaya Diagnostic Centre: +72%
Medinova Diagnostic Services: +52%
Metropolis Healthcare: +42%
Dr Lal Pathlabs: +42%

Analysts are bullish on companies like RPG Life Sciences, Indoco Remedies, FDC, Torrent Pharma, JB Pharma, Krsnaa Diagnostics, and Thyrocare, which he believes are poised for substantial expansion.

According to a recent report by HDFC Securities, the hospital segment has transitioned from its capex phase (adding bed capacity over FY14-19) to the execution phase, focusing on improving occupancy and average revenue per occupied bed, which is expected to enhance margins.

The Indian diagnostics market, recovering post-COVID, is projected to see an 8-9% CAGR over the next four years, driven by:

• Increased volumes
• Price hikes in select tests
• Expansion of wellness services
• Geographical expansion

However, the market faces challenges from increasing competition and steep discounts offered by online peers.